There are no drugs or drugs that can guarantee full protection of Coronavirus.
Even vaccines given at this time can only reduce the risk of severe symptoms.
The risk of breakthrough infections is higher among those who have compromised immunity and older adults.
They are even more susceptible to death.
But a new study shows that ancient Greece drugs to treat gout may have the potential to reduce the risk of death from Covid-19 by 50 percent.
COLCHICINE The drug comes from the Colchicum plant family, which was first used for special healing properties by the ancient Greeks.
According to the experts from the Hebrew University of Jerusalem, it began to be widely used from the first century as a treatment for gout and other inflammatory conditions, and is one of several drugs that have survived to modern times, daily letters report.
To test the effects of the drug, the team conducted a review of four controlled studies, involving 6,000 coronavirus patients from Canada, Greece, Spain and Brazil.
Each shows “clear benefits” of its use.
Israeli researchers found “a significant increase in the severe coronavirus index and most importantly, there was a decrease in mortality of around 50 percent compared to those who were not treated with Colchicine”.
The team noted that the drug was cheap and only needed half a milligram dose per day.
Prof.
Ami Schattner said that Colchicine worked to improve the results of Covid-19 patients were “important discoveries that could significantly contribute to increasing the morbidity and mortality of many patients, if confirmed in further study”.
This is because, and being cheap, it is well tolerated by patients with minimal side effects such as diarrhea attacks at 10 percent of patients, the report said.
Further randomized trials are needed, which involves drugs and patients Covid-19, to confirm the results of this ‘preliminary study’, Schattner was quoted.
However, the Indian research team from Gmers Medical College Gotri in Gujarat in November, conducted six studies meta-analysis and found that Colchicine did not prevent severe Covid cases.
“Colchicine does not reduce the risk of death, the need for ventilation support, acceptance of intensive care units or long lives in hospitals among patients with Covid-19,” the researchers wrote.
“There are no additional benefits to add Colchicine to supportive care in managing patients with Covid-19,” he added
Of the six, four studies also examined whether the drug could reduce the hospitalization of Covid-19 hospitals.
The combined results did not find the difference in mortality among people who used Colchicine and those who did not, the report said.
Likewise, in March, the British big trial stopped registration to test Colchicine as a potential treatment for patients who were hospitalized with Covid-19 after the sub-study of the trial found that the drug had no effect on patients.
However, Schattner stressed the results “very promising” and worthy of further explore, said the report.
(With input from IANs)